GLP-1 sales likely plateaued in Aug after initial surge, says Pharmatrac
This story was originally published at 12:58 IST on 7 September 2026
Register to read our real-time news.Informist, Monday, Sept. 7, 2026
Please click here to read all liners published on this story
--Pharmatrac: GLP-1 mkt showing signs of plateauing in Aug
--CONTEXT: Comments by Pharmatrac's analysts at webinar
--Pharmatrac: Aug didn't see surge in GLP-1 pdts earlier witnessed in Jun-Jul
--Pharmatrac: Tirzepatide injection volume tad down Aug, but value trend up
--Pharmatrac: New launches aided growth in antidiabetes therapy mkt in Aug
--Pharmatrac: Mounjaro maintained top position in Aug in value, unit terms
--Pharmatrac: Indian pharmaceutical mkt value YoY growth 10.7% in August
--Pharmatrac:Injectables shr in GLP-1 pdts rises to 86% in Aug vs 46% yr ago
--Pharmatrac: Tirzepatide, semaglutide dominated GLP-1 mkt in August
--Pharmatrac: Anti-infectives, respiratory therapy volume dn 3-8% YoY in Aug
--Pharmatrac: Vitamin, mineral, nutraceutical therapy value up 16.2% YoY Aug
--Pharmatrac: Cardiac therapy value up 15.1% on year in August
MUMBAI/NEW DELHI – India's glucagon-like peptide-1 agonist market is showing signs of plateauing in August after a sharp surge in sales during Jun-Jul following the launch of generic products, said Sheetal Sapale, vice president-commercial at Pharmatrac at a webinar on the Indian pharmaceutical market's August performance.
"There was a significant jump that was seen in the units last month. But again, now this month, we are seeing a plateauing," Sapale said Monday. The surge witnessed between June and July for semgalutide products did not continue in August, she said.
The glucagon-like peptide-1 market, comprising solids and injectables, is valued at INR 23.33 billion as of August, with tirzepatide accounting for 62% of the market and semaglutide contributing 34%. The two therapies together account for more than 96% of the segment. The market is also seeing a clear shift towards injectable products with injectables accounting for 86% of the GLP-1 market in August, compared with 14% for solids, according to Pharmatrac's data.
Semaglutide solids saw a significant dip in August, which may indicate a shift in patient preference towards injections, Pharmatrac said. "So somewhere, we are seeing that the popularity that had moved up significantly, that is coming down. And this may be leading to preference for injections," Sapale said.
The overall Indian pharmaceutical market recorded a 10.7% year-on-year growth in value during August, with all three growth levers--price, volume, and new product launches--positive. However, volume growth was slightly subdued compared with the previous two-three months. Meanwhile, new launches boosted growth in the anti-diabetes therapy market. Insulin, which had previously declined, picked up significantly in terms of volume growth over the last four to five months.
Mounjaro maintained the number one position among brands in both monthly and annual terms, with monthly sales of close to INR 1 billion, Sapale said. Among major therapies, cardiac therapy value grew 15.1% on year in August, while vitamin, mineral, and nutraceutical therapy value rose 16.2% on year. Anti-infectives and respiratory therapies volume declined 3-8% on year in August, in line with seasonal trends.
Other therapies showed strong volume growth including heart-failure and antithrombotic therapies in cardiac care, insulin in anti-diabetes, systemic antihistamines in respiratory care, rheumatoid arthritis drugs in pain management, haircare products in dermatology, myo-inositol in gynaecology, and monoclonal antibodies across therapy areas. End
Reported by Gunjan Rajput and Anshul Choudhary
Edited by Akul Nishant Akhoury
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.
Informist Media Tel +91 (11) 4220-1000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2026. All rights reserved.
To read more please subscribe
Share this Story:
